Tofacitinib
Sign in to save this workspacePrimary targets: JAK3 · FDA status: FDA Approved
Selectivity scorecard
KISS
99.25
Gini
0.684
CATDS
0.045
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Tofacitinib. Strongest target: JAK3 at 98.2% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | JAK3 | 98.2% | 1.8% |
| 2 | JAK1 | 95.2% | 4.8% |
| 3 | JAK2 | 92.3% | 7.7% |
| 4 | TYK2 | 81.0% | 19.0% |
| 5 | PKN1_PRK1 | 55.8% | 44.2% |
| 6 | PDK2_PDHK2 | 35.2% | 64.8% |
| 7 | CAMKK2 | 33.0% | 67.0% |
| 8 | TNK1 | 30.1% | 69.9% |
| 9 | CK1D | 25.1% | 74.9% |
| 10 | CDK9_CYCLIN_T1 | 22.6% | 77.4% |
| 11 | PKCD | 20.7% | 79.3% |
| 12 | MUSK | 20.2% | 79.8% |
| 13 | VRK1 | 19.7% | 80.3% |
| 14 | PKMYT1 | 19.3% | 80.7% |
| 15 | STK38_NDR1 | 19.1% | 80.9% |
| 16 | PKN2_PRK2 | 18.5% | 81.5% |
| 17 | LRRK2 | 17.8% | 82.2% |
| 18 | P38A_MAPK14 | 17.6% | 82.4% |
| 19 | PKG2_PRKG2 | 17.5% | 82.5% |
| 20 | PDK1_PDPK1 | 17.3% | 82.7% |
Selectivity landscape
Where Tofacitinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Tofacitinib.
Atlas insights for Tofacitinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.836 |
| C3L-03726 | — | 0.829 |
| SRR10899984 | — | 0.822 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.820 |
| TCGA-CV-7424-01A-11R-2081-07 | — | 0.817 |
Annotations
Sign in to read and post annotations.
Loading…